The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: Tocilizumab is a humanized monoclonal antibody which targets and inhibits interleukin-6 (IL-6) and has demonstrated efficacy in treating diseases associated with hyper-inflammation. Data are suggestive of tocilizumab as a potential treatment for patients with COVID-19 infection. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotter, Aoife, Wallace, Deborah, McCarthy, Cormac, Feeney, Eoin, O’Neill, Lorraine, Stack, John, McCarthy, Geraldine, Hussain, Rabia, Alvarez Barco, Elena, Doran, Peter, Mallon, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468092/
https://www.ncbi.nlm.nih.gov/pubmed/32883328
http://dx.doi.org/10.1186/s13063-020-04680-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468092/
https://www.ncbi.nlm.nih.gov/pubmed/32883328
http://dx.doi.org/10.1186/s13063-020-04680-w

Ejemplares similares